Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$25.24
+5.8%
$24.02
$13.74
$70.43
$5.52B2.4322.23 million shs22.66 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,085.36
+1.9%
$948.23
$623.78
$1,133.95
$1.00T0.483.34 million shs2.58 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
+0.33%+5.90%-22.31%+49.76%-56.66%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.02%+4.82%+20.56%+3.54%+49.41%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$25.24
+5.8%
$24.02
$13.74
$70.43
$5.52B2.4322.23 million shs22.66 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,085.36
+1.9%
$948.23
$623.78
$1,133.95
$1.00T0.483.34 million shs2.58 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
+0.33%+5.90%-22.31%+49.76%-56.66%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.02%+4.82%+20.56%+3.54%+49.41%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.12
Hold$28.7013.72% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,227.0013.05% Upside

Current Analyst Ratings Breakdown

Latest LLY and HIMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,133.00 ➝ $1,251.00
5/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Set Price Target$1,119.00
5/26/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Lower Price TargetNeutral$28.00 ➝ $25.00
5/22/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Set Price Target$23.00
5/22/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Boost Price TargetHold$18.00 ➝ $23.00
5/22/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingBuy$1,283.00
5/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,350.00
5/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform
5/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price Target$1,300.00 ➝ $1,330.00
5/19/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy (B)Buy (B-)
5/19/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Lower Price TargetNeutral$30.00 ➝ $28.00
(Data available from 5/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$2.35B2.49$0.89 per share28.50$1.93 per share13.08
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B15.68$25.62 per share42.36$33.13 per share32.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$128.37M-$0.09N/A51.5046.28-0.56%6.10%1.52%8/10/2026 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1538.5624.481.1634.98%105.77%23.76%8/5/2026 (Estimated)

Latest LLY and HIMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.04-$0.40-$0.44-$0.40$616.84 million$608.10 million
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.64%+15.18%24.58%11 Years

Latest LLY and HIMS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.18
1.69
1.56
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10

Institutional Ownership

CompanyInstitutional Ownership
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
63.52%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
11.76%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2,442231.46 million204.24 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable

Recent News About These Companies

The $4 Billion Reason Eli Lilly Stock Is Up Today

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Hims & Hers Health stock logo

Hims & Hers Health NYSE:HIMS

$25.24 +1.39 (+5.82%)
Closing price 03:59 PM Eastern
Extended Trading
$25.22 -0.01 (-0.05%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,085.36 +20.62 (+1.94%)
Closing price 03:59 PM Eastern
Extended Trading
$1,085.75 +0.39 (+0.04%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.